ASTELLAS PHARMA INC. Tokyo, October 30, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, 'Astellas') today announced that Astellas and MicroBiopharm Japan Co., Ltd. (Headquarters: Tokyo, President: Masanobu Suzuki, 'MBJ') have concluded an agreement, under which the business of Kiyosu Plant (Kiyosu-shi, Aichi), the manufacturing site, will be transferred to MBJ.
Outline of Transfer of Kiyosu Plant Business
Purpose of Transfer
Astellas is engaged in ongoing efforts to create organizations and systems that can flexibly respond to rapidly changing environments and work toward higher quality and efficiency of operations. In the areas of manufacturing and technology as well, Astellas strives to promote the establishment of a stable manufacturing system that would efficiently realize 'steady supply of high-quality drugs' in changing environment. As a part of these efforts, Astellas has reached an agreement with MBJ under which the pharmaceutical manufacturing business of Kiyosu Plant will be transferred to MBJ.
The transfer of the Kiyosu Plant business will make Astellas aim to ensure higher quality and efficiency in its manufacturing and technology functions.
The pharmaceutical substances currently manufactured at the Kiyosu Plant are planned to be continuously manufactured there as outsourcing products to MBJ.
MBJ is a CMO that has over 50 years' experience and technology in fermentation, genetic recombination. Those knowledge and achievements can be applicable to production of the pharmaceutical substances currently manufactured at Kiyosu plant. Taking this opportunity, MBJ will further strengthen and deepen their CMO business in Bio-pharmaceutical fields.
Assets Subject to Transfer
Real estate, movable properties (including facilities and equipment) and pharmaceutical manufacturing business at the Kiyosu Plant
Financial Terms
Financial terms including the value of this transfer are not disclosed.
Schedule for Business Transfer
October 30, 2015 : Execution of an agreement April 1, 2016 (tentative): Transfer of business
Outline of Kiyosu Plant
Location: 156 Nakagawara, Kiyosu-shi, Aichi Site area: 21,139.18 m2
Building area: 3,270.27 m2
Business description: Manufacturing of pharmaceutical substances
Outline of Transferee Company MicroBiopharm Japan Co., Ltd.
Head office: 1-3-1 Kyobashi, Chuo-ku, Tokyo Representative: President, Masanobu Suzuki Capital: 10 million yen (as of July 1, 2015)
Shareholders: Mitsui & Co., Ltd. 80%, Toray Industries, Inc. 20%
Business description: Manufacturing, sales, research and development of pharmaceutical products
Total number of employees: 293 (as of July 1, 2015)
The impact of the execution of this agreement has been accounted in revised Astellas' forecasts for fiscal year ending March 2016, which was announced on October 30, 2015.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
###
Contacts for inquiries or additional information Astellas Pharma Inc.
Corporate Communications
TEL: 03-3244-3201 FAX: 03-5201-7473
http://www.astellas.com/en
|
distributed by
|
